Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $57.80 | Total: $289.00 |
| 1 | 10 | $48.96 | Total: $489.60 |
| 1 | 25 | $41.48 | Total: $1,037.00 |
| 1 | 50 | $35.36 | Total: $1,768.00 |
| 1 | 100 | $30.60 | Total: $3,060.00 |
Overview
Inavolisib (GDC-0077) is an orally available and selective inhibitor of PI3K? (IC50=0.038 nM). Inavolisib is more selective for mutant versus wild-type PI3K?. Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
Chemical Properties
| Molecular Formula | C18H19F2N5O4 |
| Molecular Weight | 407.37 |
| CAS Numbers | 2060571-02-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
R Hong, Abstract PD4-14 GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium.